Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.
Clinically significant ILD is believed to occur in 5%-10% of patients with RA, but robust data are lacking on how to best predict which patients face the highest risk for RA-associated ILD.
Telitacicept is a recombinant fusion protein that aims to target and neutralize B lymphocyte stimulator and a proliferation-inducing ligand (APRIL), both of which are linked to autoimmunity.
RA is an autoimmune disease where body's immune system mistakenly attacks its own joints, leading to inflammation and joint damage. Chronic inflammation and immune dysfunction in RA may contribute to an increased risk of lymphoma, condition where abnormal white blood cells divide uncontrollably.